Sanya Sukduang is an attorney in Finnegan, Henderson, Farabow, Garrett & Dunner, LLP’s Washington, D.C. office. His practice concentrates on patent litigation before federal district courts and the U.S. Court of Appeals for the Federal Circuit, and post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), primarily in the areas of biotechnology, pharmaceuticals, biologics, diagnostics, and medical devices. He has conducted all aspects of pre-trial, trial, post-trial, and inter partes review (IPR) proceedings before the PTAB. Mr. Sukduang has extensive experience in cases arising from the filing of Abbreviated New Drug Applications (ANDA). He advises clients on an array of issues concerning biologics, including due diligence investigations and strategic patent portfolio planning. Mr. Sukduang lectures in the United States and abroad on biologics and biosimilars arising under the Biologics Price Competition and Innovation Act (BPCIA) and has authored numerous articles on this topic. Mr. Sukduang holds a JD from American University.